Skip to main content
. 2008 Apr 23;8:115. doi: 10.1186/1471-2407-8-115

Table 4.

Hepatic dysfunction occurrence rates based ons Rituximab administration

Use of rituximab Patients with hepatic dysfunction (N = 40) (49.4%) Patients without hepatic dysfunction (N = 41) (50.6%) p-value
Yes 13 (32.5) 14(34.1) 0.88
No 27(67.5) 27(65.9)